Avirmax Biopharma Inc.
🇺🇸United States
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)
Phase 1
Recruiting
- Conditions
- Neovascular (Wet) AMD
- Interventions
- Drug: ABI-110 High DoseDrug: ABI-110 Low DoseDrug: ABI-110 Medium Dose
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Avirmax Biopharma Inc
- Target Recruit Count
- 18
- Registration Number
- NCT06550011
- Locations
- 🇺🇸
California Retina Consultants, Bakersfield, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
🇺🇸Retina Consultants of Texas - San Antonio, San Antonio, Texas, United States
News
No news found